Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Hydralazine

4

III.b Pneumorenal syndrome (w/wo ANCAs)

1
Last update : 14/04/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Current cardiology reviews 2021;17;182-187 2021
Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Journal of medical case reports 2020 Apr 15;14;47 2020 Apr 15
Hereditary afibrinogenemia and pulmonary-renal hydralazine-induced vasculitis.
Proceedings (Baylor University. Medical Center) 2019 Jul;32;397-398 2019 Jul
Hydralazine-induced pulmonary-renal syndrome: a case report.
American journal of therapeutics 2012 Jul;19;e136-8 2012 Jul
Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.
International urology and nephrology 2012 Dec;44;1907-9 2012 Dec
Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.
Modern rheumatology 2009;19;338-47 2009

Powered by

  • ^
  • Contact
  • Cookies
  • About